Future Development

The framework can support co-production across research prioritisation, design, conduct, dissemination, and uptake. The preferred simulated favipiravir regimen was 2,400 mg twice daily on day 1 followed by 1,600 mg twice daily from days 2-10. Dosing simulations suggested that a lower favipiravir loading dose and higher maintenance dose could preserve antiviral exposure while reducing peak-related adverse reaction risk. Further development is underway in the INTEGRATE platform trial to identify next-generation antiviral and adjunct treatments for Lassa fever. The framework is intended to be a living tool rather than a final taxonomy. The findings support further clinical evaluation of favipiravir alone or in combination regimens, including in severe Lassa fever. Future work should map NHS-SOS against relevant domain ontologies and examine how users interact with classification systems.